CFS Biomedical Partnership

CFS Biomedical is a biotechnology company focused on developing a diagnostic test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The company utilizes a nanoneedle biosensor technology, developed at the Stanford Genome Technology Center, which measures cellular responses to salt stress in blood samples. This platform aims to provide a definitive biomarker for a condition that has historically lacked objective diagnostic tools. By detecting minute changes in electrical impedance, the technology can distinguish between healthy individuals and those with ME/CFS with high accuracy. While the company gained significant attention for its potential to revolutionize ME/CFS diagnosis and drug screening, its current operational status is largely inactive as the technology continues to be refined in academic settings.